Azurity Pharmaceuticals entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors, including JW Asset Management and KKR.
Azurity Pharmaceuticals was born as a corporate identity in June 2019 with the acquisition of Silvergate Pharmaceuticals by CutisPharma.
NovaQuest Capital Management, which supported CutisPharma and its management team in the transaction, became the majority owner of the new entity, which focused on developing drug delivery technologies to provide customized dosage forms to patients. The value of that transaction was not disclosed, but it was backed by NovaQuest Fund I, which held its final close . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.
Monthly subscriptions and discounted corporate plans for up to 100 members also available.